ConductScience.org, home

Paper30026331

Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis.

Shabaneh TB and 9 others. Cancer Res, 2018. Cited by 93 papers, by iCite.

Cite this record

ConductScience Library. Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. Papers, record 30026331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30026331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis.
PubMed
Journal
Cancer Res
PubMed
Year
2018
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
93
iCite
Relative citation ratio, by iCite
2.5
iCite
Revised in PubMed
2023-09-08
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shabaneh TBTamer B
2Molodtsov AKAleksey K
3Steinberg SMShannon M
4Zhang PPeisheng
5Torres GMGretel M
6Mohamed GAGadisti Ahttps://orcid.org/0000-0002-4880-5110
7Boni AAndrea
8Curiel TJTyler J
9Angeles CVChristina V
10Turk MJMary Jo

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinogenesisMajor topic
MelanomaMajor topic
Proto-Oncogene Proteins B-rafMajor topic
T-Lymphocytes, RegulatoryMajor topic
Animals
Antigens, Neoplasm
CD8-Positive T-Lymphocytes
Cell Line, Tumor
Disease Models, Animal
Gene Expression Regulation, Neoplastic
Humans
Lymph Nodes
Melanocytes
Mice
Mutation
PTEN Phosphohydrolase
Receptors, CCR4
Tumor Microenvironment

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA023108NCI NIH HHSUnited StatesP30CA023108PubMed and NIHNIH RePORTER
R01 CA120777NCI NIH HHSUnited StatesR01CA120777PubMed and NIHNIH RePORTER
R01 CA214062NCI NIH HHSUnited StatesR01CA214062PubMed and NIHNIH RePORTER
R21 CA209375NCI NIH HHSUnited StatesR21CA209375PubMed and NIHNIH RePORTER
R01 CA205965NCI NIH HHSUnited StatesR01CA205965PubMed and NIHNIH RePORTER
T32 AI007363NIAID NIH HHSUnited StatesT32AI007363PubMedNIH RePORTER
R01 CA225028NCI NIH HHSUnited StatesR01CA225028PubMed and NIHNIH RePORTER
P30 GM103415NIGMS NIH HHSUnited StatesP30GM103415PubMed and NIHNIH RePORTER

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117000676Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.Clin Cancer Res2006https://conductscience.org/library/papers/17000676PubMed
217001349Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells.Oncogene2007https://conductscience.org/library/papers/17001349PubMed
321873989Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Nat Med2011https://conductscience.org/library/papers/21873989PubMed
416079850BRAFE600-associated senescence-like cell cycle arrest of human naevi.Nature2005https://conductscience.org/library/papers/16079850PubMed
517615234Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17615234PubMed
617596146Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases.Br J Dermatol2007https://conductscience.org/library/papers/17596146PubMed
727642636Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.JCI Insight2016https://conductscience.org/library/papers/27642636PubMed
823471412Aire-dependent thymic development of tumor-associated regulatory T cells.Science2013https://conductscience.org/library/papers/23471412PubMed
923640603Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions.Cancer Immunol Immunother2013https://conductscience.org/library/papers/23640603PubMed
1025790431Transcriptional regulation of chemokine expression in ovarian cancer.Biomolecules2015https://conductscience.org/library/papers/25790431PubMed
1127521269Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.Immunity2016https://conductscience.org/library/papers/27521269PubMed
1216618776Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.Cancer Res2006https://conductscience.org/library/papers/16618776PubMed
1323986400Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.Sci Transl Med2013https://conductscience.org/library/papers/23986400PubMed
1425970248Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.Nature2015https://conductscience.org/library/papers/25970248PubMed
1525183499BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.Cancer Immunol Res2014https://conductscience.org/library/papers/25183499PubMed
1621156649Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.Cancer Res2011https://conductscience.org/library/papers/21156649PubMed
1717616708Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.Cancer Res2007https://conductscience.org/library/papers/17616708PubMed
1817312132Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.J Immunol2007https://conductscience.org/library/papers/17312132PubMed
1923454771Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.J Clin Invest2013https://conductscience.org/library/papers/23454771PubMed
2014738769Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy.Immunity2004https://conductscience.org/library/papers/14738769PubMed

See all 49 referencesDownload CSV of references

Cited by65

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.

PMIDTitleJournalYearIn PapersSource
42920839Regulatory T cell heterogeneity: who they are, where they come from, and where they go.Front Immunol2026https://conductscience.org/library/papers/42920839PubMed
42906944Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.J Immunother Cancer2026https://conductscience.org/library/papers/42906944PubMed
42769030Spatial Treg niches and the therapeutic reprogramming of tumour tolerance in cancer.Front Cell Dev Biol2026https://conductscience.org/library/papers/42769030PubMed
42552305Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42552305PubMed
42523496The initial melanoma T cell infiltrate is defined by tissue-resident programs restrained by regulatory T cells.Res Sq2026https://conductscience.org/library/papers/42523496PubMed
42212208Phenotypic alterations in the immune system and tolerance induction in tumor-draining lymph nodes.Iran J Basic Med Sci2026https://conductscience.org/library/papers/42212208PubMed
42098518Homeobox A10 in gastrointestinal malignancies: unraveling metastatic mechanisms and novel therapeutic opportunities.Cancer Metastasis Rev2026https://conductscience.org/library/papers/42098518PubMed
41868670BRAF mutation and tumor immune microenvironment in new era.Am J Cancer Res2026https://conductscience.org/library/papers/41868670PubMed
41851514Mucosal melanoma of the head and neck region: clinical-pathologic implications of tumor microenvironment evaluated with multiplex immunohistochemistry.Virchows Arch2026https://conductscience.org/library/papers/41851514PubMed
41813655Chemokine-chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming.Chin Med J (Engl)2026https://conductscience.org/library/papers/41813655PubMed
41575516Integrated approaches to sensitizing melanoma to radiotherapy.Strahlenther Onkol2026https://conductscience.org/library/papers/41575516PubMed
41482575The immunology of vitiligo.Nat Rev Immunol2026https://conductscience.org/library/papers/41482575PubMed
41446197Cellular interactions in the sentinel lymph node predict melanoma recurrence.bioRxiv2025https://conductscience.org/library/papers/41446197PubMed
41279375Regulatory T cells inhibit CD8+ TRM-like cells during the early stages of tumor immune escape.bioRxiv2025https://conductscience.org/library/papers/41279375PubMed
41258633Relationship between the BRAF-V600E variant allele frequency and clinicopathological characteristics of papillary thyroid carcinoma and its clinical application.Discov Oncol2025https://conductscience.org/library/papers/41258633PubMed
41225509Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.J Transl Med2025https://conductscience.org/library/papers/41225509PubMed
41087343Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential.Signal Transduct Target Ther2025https://conductscience.org/library/papers/41087343PubMed
40866864Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.BMC Cancer2025https://conductscience.org/library/papers/40866864PubMed
40831885Autologous Tumor-Infiltrating Lymphocyte Infusion plus Anti-Programmed Cell Death Protein 1 Therapy to Cure Advanced Hepatocellular Carcinoma following Palliative Hepatectomy.Liver Cancer2025https://conductscience.org/library/papers/40831885PubMed
40749665Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells.Immunity2025https://conductscience.org/library/papers/40749665PubMed

See all 65 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CCR41233PubTator's text mininghttps://conductscience.org/library/genes/1233NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
FOXP350943PubTator's text mininghttps://conductscience.org/library/genes/50943NCBI Gene
PMEL6490PubTator's text mininghttps://conductscience.org/library/genes/6490NCBI Gene
PTEN5728PubTator's text mininghttps://conductscience.org/library/genes/5728NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30026331

GET https://conductscience.org/api/papers/v1/30026331/references?page=2